NovusTex is a regenerative bioengineering company that bioprints nasal cartilage tissue to accelerate drug development and advance facial reconstruction solutions. Its reproducibility-driven platform enables intranasal toxicity testing, formulation optimization, and drug absorption studies using standardized fabrication workflows and controlled tissue architecture. The platform supports translational preclinical screening today while building toward future craniofacial reconstruction applications.
Funding
Funding not disclosed
Founders
Product
Problem
Traditional preclinical drug development relies on animal models and simplified in vitro systems that poorly replicate human nasal tissue, leading to inaccurate predictions of drug absorption, toxicity, and local tissue interactions. This gap contributes to costly late-stage drug failures and limits the development of intranasal therapeutics. Additionally, existing approaches lack reproducibility and standardization needed for reliable translational screening.
Solution
NovusTex provides a regenerative bioengineering platform that bioprints human nasal cartilage tissue for use in drug development and future regenerative medicine applications. The platform enables intranasal toxicity testing, formulation optimization, drug absorption and diffusion studies, and local tissue interaction analysis within a physiologically relevant human tissue model. By employing controlled tissue architecture, standardized fabrication workflows, and iterative testing processes, NovusTex ensures reproducible results suitable for translational preclinical screening. The platform is designed to accelerate intranasal therapeutic development today while building toward advanced craniofacial reconstruction applications, offering a more predictive alternative to traditional testing methods.
Target Audience
Primary customers are pharmaceutical and biotechnology companies developing intranasal therapeutics, as well as clinical researchers focused on craniofacial reconstruction and regenerative medicine applications.
Features
- 3D-bioprinted human nasal cartilage tissue models that replicate native tissue structure and function for preclinical testing
- Intranasal toxicity testing and formulation optimization capabilities for drug developers
- Drug absorption, diffusion, and local tissue interaction studies using human-relevant tissue constructs
- Standardized fabrication workflows with controlled tissue architecture to ensure batch-to-batch reproducibility
- Translational preclinical screening platform designed to bridge the gap between in vitro studies and clinical application
- Iterative testing and optimization protocols to refine tissue engineering approaches and therapeutic outcomes